Phase 3 study for people with Multiple Sclerosis

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Novartis Pharmaceuticals
Registry number NCT06846281
Started 23 June 2025 Today 16 October 2026 Estimated completion 25 July 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Novartis Investigative Site Melbourne VIC Recruiting
Novartis Investigative Site Parkville VIC Recruiting
Novartis Investigative Site Liverpool NSW Withdrawn
Novartis Investigative Site St Leonards NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 40 Years to 70 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 400

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Key Inclusion Criteria:

* Male or female aged 40 to 70 years (inclusive)

* Diagnosis of RMS according to the 2017 McDonald diagnostic criteria

* Treated with ocrelizumab according to routine clinical practice and at standard dose

* Neurologically stable within 30 days

* Suitable to be switched to remibrutinib based on physician judgement or patient preference

Key Exclusion Criteria:

* Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria

* History of clinically significant Central Nervous System disease or neurological disorders

* History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent

* Active clinically significant systemic bacterial, viral, parasitic or fungal infections

* Active, chronic disease of the immune system other than MS

* Severe cardiac disease or significant findings on the ECG

* Participant who is unable to undergo MRI scans

* History of life-threatening infusion or injection reaction related to ocrelizumab

* Participants not adequately controlled on ocrelizumab (CD19+ B-cell count ≥10 cells/µL at screening)

Other inclusion and exclusion criteria may apply

Dates on the record

Started 23 June 2025
Estimated completion 25 July 2029
Registry last updated 26 August 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 26 August 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.